The serine protease HtrA1 specifically interacts and degrades the tuberous sclerosis complex 2 protein

Molecular Cancer Research

Volumn 8, Issue 9, 2010, Pages 1248-1260

  Campioni, Mara ^a   Severino, Anna ^c   Manente, Lucrezia ^a   Tuduce, Ioana L ^a   Toldo, Stefano ^c   Caraglia, Michele ^a   Crispi, Stefania ^b   Ehrmann, Michael ^d   He, Xiaoping ^e   Maguire, Jacie ^e   De Falco, Maria ^b   De Luca, Antonio ^a   Shridhar, Viji ^e   Baldi, Alfonso ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

^d UNIVERSITY OF DUISBURG ESSEN   (Germany)

^e Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN HTRA1; SERINE PROTEINASE; TUBERIN; UNCLASSIFIED DRUG;

ARTICLE; BINDING ASSAY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOPLASM; DOWN REGULATION; EMBRYO DEVELOPMENT; ENZYME DEGRADATION; ENZYME PHOSPHORYLATION; FETUS DEVELOPMENT; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; IMMUNOELECTRON MICROSCOPY; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TWO HYBRID SYSTEM; WESTERN BLOTTING;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; CELL LINE; CLONE CELLS; CYTOPLASM; DOWN-REGULATION; EXTRACELLULAR SPACE; FEMALE; HUMANS; IMMUNOPRECIPITATION; MUTANT PROTEINS; PHOSPHOPROTEINS; PHOSPHORYLATION; PLACENTA; PREGNANCY; PROTEIN BINDING; PROTEIN INTERACTION MAPPING; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN TRANSPORT; RECOMBINANT FUSION PROTEINS; REPRODUCIBILITY OF RESULTS; RIBOSOMAL PROTEIN S6 KINASES; SERINE ENDOPEPTIDASES; TUMOR SUPPRESSOR PROTEINS;

EID: 77957109673     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-09-0473     Document Type: Article

References (57)

1. Oka C, Tsujimoto R, Kajikawa M, et al. HtrA1 serine protease inhibits signaling mediated by Tgfβ family proteins. Development 2004;131:1041-53.
2. Swisshelm K, Ryan K, Tsuchiya K, Sager R. Enhanced expression of an insulin growth factor-like binding protein (mac25) in senescent human mammary epithelial cells and induced expression with retinoic acid. Proc Natl Acad Sci U S A 1995;92:4472-6.
3. Kato MV, Sato H, Tsukada T, Ikawa Y, Aizawa S, Nagayoshi M. A follistatin-like gene, mac25, may act as a growth suppressor of osteosarcoma cells. Oncogene 1996;12:1361-4. (Pubitemid 3037454)
4. Hu SI, Carozza M, Klein M, Nantermet P, Luk D, Crowl RM. Human HtrA, an evolutionarily conserved serine protease identified as a differentially expressed gene product in osteoarthritic cartilage. J Biol Chem 1998;273:34406-12.
5. Murwantoko , Yano M, Ueta Y, et al. Binding of proteins to the PDZ domain regulates proteolytic activity of HtrA1 serine protease. Biochem J 2004;381:895-904.
6. Grau S, Richards PJ, Kerr B, et al. The role of human HtrA1 in arthritic disease. J Biol Chem 2006;281:6124.
7. Tsuchiya A, Yano M, Tocharus J, et al. Expression of mouse HtrA1 serine protease in normal bone and cartilage and its upregulation in joint cartilage damaged by experimental arthritis. Bone 2005;37:323-36. (Pubitemid 41160491)
8. Grau S, Baldi A, Bussani R, et al. Implications of the serine protease HtrA1 in amyloid precursor protein processing. Proc Natl Acad Sci U S A 2005;102:6021-6.
9. Zumbrunn J, Trueb B. Primary structure of a putative serine protease specific for IGF-binding proteins. FEBS Lett 1996;398:187-92.
10. Baldi A, De Luca A, Morini M, et al. The HtrA1 serine protease is down-regulated during human melanoma progression and represses growth of metastatic melanoma cells. Oncogene 2002;21:6684-8.
11. Chien J, Staub J, Hu SI, et al. A candidate tumor suppressor HtrA1 is downregulated in ovarian cancer. Oncogene 2004;23:1636-44.
12. Esposito V, Campioni M, De Luca A, et al. Analysis of HtrA1 serine protease expression in human lung cancer. Anticancer Res 2006;26:3455-9.
13. Baldi A, Mottolese M, Vincenzi B, et al. The serine protease HtrA1 is a novel prognostic factor for human mesothelioma. Pharmacogenomics 2008;9:1069-77.
14. Chien J, Campioni M, Shridhar V, Baldi A. HtrA serine proteases as potential therapeutic targets in cancer. Curr Cancer Drug Targets 2009;9:451-68.
15. DeWan A, Liu M, Hartman S, Zhang SS, Liu DT, Zhao C. HtrA1 promoter polymorphism in wet age-related macular degeneration. Science 2006;314:989-92.
16. Yang Z, Camp NJ, Sun H, et al. A variant of the HTRA1 gene increases susceptibility to age-related macular degeneration. Science 2006;314:992-3.
17. Weger M, Renner W, Steinbrugger I, et al. Association of the HTRA1- 625G>A promoter gene polymorphism with exudative age-related macular degeneration in a Central European population. Mol Vis 2007;13:1274-9.
18. Rivera A, Fisher SA, Fritsche LG, et al. Hypothetical LOC387715 is a second major susceptibility gene for age-related macular degeneration, contributing independently of complement factor H to disease risk. Hum Mol Genet 2005;14:3227-36. (Pubitemid 41631297)
19. Jakobsdottir J, Conley YP, Weeks DE, Mah TS, Ferrell RE, Gorin MB. Susceptibility genes for age-related maculopathy on chromosome 10q26. Am J Hum Genet 2005;77:389-407.
20. Cheadle JP, Reeve MP, Kwiakowski DJ. Molecular genetic advances in tuberous sclerosis. Hum Genet 2000;107:97-114.
21. Green AJ, Smith M, Yates JR. Loss of heterozygosity on chromosome 16p13.3 in hamartomas from tuberous sclerosis patients. Nat Genet 1994;6:193-6. (Pubitemid 24188602)
22. Green AJ, Johnson PH, Yates JR. The tuberous sclerosis gene on chromosome 9q34 acts as a growth suppressor. Hum Mol Genet 1994;3:1833-4.
23. van Slegtenhorst M, de Hoogt R, Hermans C, et al. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science 1997;277:805-8.
24. European Chromosome 16 Tuberous Sclerosis Consortium. Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell 1993;75:1305-15.
25. Plank TL, Yeung RS, Henske EP. Hamartin, the product of the tuberous sclerosis 1 (TSC1) gene, interacts with tuberin and appears to be localized to cytoplasmic vesicles. Cancer Res 1998;58:4766-70.
26. van Slegtenhorst M, Nellist M, Nagelkerken B, et al. Interaction between hamartin and tuberin, the TSC1 and TSC2 gene products. Hum Mol Genet 1998;7:1053-7.
27. Inoki K, Li Y, Xu T, Guan KL. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev 2003;17:1829-34. (Pubitemid 36944560)
28. Choo AY, Yoon SO, Kim SG, Roux PP, Blenis J. Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proc Natl Acad Sci U S A 2008;105:17414-9.
29. Gingras AC, Gygi SP, Raught B, et al. Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism. Genes Dev 1999;13:1422-37.
30. Avruch J, Hara K, Lin Y, et al. Insulin and amino-acid regulation of mTOR signaling and kinase activity through the Rheb GTPase. Oncogene 2006;25:6361-72.
31. Leonetti C, Biroccio A, Candiloro A, et al. Increase of cisplatin sensitivity by c-myc antisense oligodeoxynucleotides in a human metastatic melanoma inherently resistant to cisplatin. Clin Cancer Res 1999;5:2588-95.
32. Chien J, Aletti G, Baldi A, et al. Serine protease HtrA1 modulates chemotherapy-induced cytotoxicity. J Clin Invest 2006;116:1994-2004. (Pubitemid 44033323)
33. Chien J, He X, Shridhar V. Identification of tubulins as substrates of serine protease HtrA1 by mixture-based oriented peptide library screening. J Cell Biochem 2009;107:253-63.
34. Benvenuto G, Brown SJ, Bravermann R, et al. The tuberous sclerosis-1(TSC1) gene product hamartin suppresses cell growth and augments the expression of the TSC2 product tuberin by inhibiting its ubiquitination. Oncogene 2000;19:6306-16.
35. De Luca A, De Falco M, Severino A, et al. Distribution of the serine protease HtrA1 in normal human tissues. J Histochem Cytochem 2003;51:1279-84. (Pubitemid 37187579)
36. De Luca A, De Falco M, De Luca L, et al. Pattern of expression of HtrA1 during mouse development. J Histochem Cytochem 2004a;52:1609-17.
37. De Luca A, De Falco M, Fedele V, et al. The serine protease HtrA1 is upregulated in the human placenta during pregnancy. J Histochem Cytochem 2004b;52:885-92.
38. Lorenzi T, Marzioni D, Giannubilo S, et al. Expression patterns of two serine protease HtrA1 forms in human placentas complicated by preeclampsia with and without intrauterine growth restriction. Placenta 2009;30:35-40.
39. Bowden MA, Di Nezza-Cossens LA, Jobling T, Salamonsen LA, Nie G. Serine proteases HTRA1 and HTRA3 are down-regulated with increasing grades of human endometrial cancer. Gynecol Oncol 2006;103:253-60.
40. Narkiewicz J, Klasa-Mazurkiewicz D, Zurawa-Janicka D, Skorko- Glonek J, Emerich J, Lipinska B. Changes in mRNA and protein levels of human HtrA1, HtrA2 and HtrA3 in ovarian cancer. Clin Biochem 2008;41:561-9.
41. Hadfield KD, Rock CF, Inkson CA, et al. HtrA1 inhibits mineral deposition by osteoblasts: requirement for the protease and PDZ domains. J Biol Chem 2008;283:5928-38.
42. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007;12:9-22.
43. Goncharova E, Goncharov D, Noonan D, Krymskaya VP. TSC2 modulates actin cytoskeleton and focal adhesion through TSC1-binding domain and the Rac1 GTPase. J Cell Biol 2004;167:1171-82.
44. Jaeschke A, Hartkamp J, Saitoh M, et al. Tuberous sclerosis complex tumor suppressor-mediated S6 kinase inhibition by phosphatidylinositide- 3-OH kinase is mTOR independent. J Cell Biol 2002;159:217-24.
45. Tee AR, Fingar DC, Manning BD, Kwiatkowski DJ, Cantley LC, Blenis J. Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc Natl Acad Sci U S A 2002;99:13571-6.
46. Kwiatkowski DJ, Zhang H, Bandura JL, et al. A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells. Hum Mol Genet 2002;11:525-34. (Pubitemid 34257489)
47. Kenerson HL, Aicher LD, True LD, Yeung RS. Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors. Cancer Res 2002;62:5645-50.
48. Karbowniczek M, Yu J, Henske EP. Renal angiomyolipomas from patients with sporadic lymphangiomyomatosis contain both neoplastic and non-neoplastic vascular structures. Am J Pathol 2003;162:491-500.
49. El-Hashemite N, Walker V, Zhang H, Kwiatkowski DJ. Loss of Tsc1 or Tsc2 induces vascular endothelial growth factor production through mammalian target of rapamycin. Cancer Res 2003;63:5173-7.
50. Huang J, Manning BD. The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochem J 2008;412:179-90.
51. Fanning AS, Anderson JM. Protein-protein interactions: PDZ domain networks. Curr Biol 1996;6:1385-8.
52. Ma S, Song E, Gao S, Tian R, Gao Y. Rapid characterization of the binding property of HtrA2/Omi PDZ domain by validation screening of PDZ ligand library. Sci China C Life Sci 2007;50:412-22. (Pubitemid 47036729)
53. Runyon ST, Zhang Y, Appleton BA, et al. Structural and functional analysis of the PDZ domains of human HtrA1 and HtrA3. Protein Sci 2007;16:2454-71.
54. Canfield AE, Hadfield KD, Rock CF, Wylie EC, Wilkinson FL. HtrA1: a novel regulator of physiological and pathological matrix mineralization? Biochem Soc Trans 2007;35:669-71.
55. Clawson GA, Bui V, Xin P, Wang N, Pan W. Intracellular localization of the tumor suppressor HtrA1/Prss11 and its association with HPV16 E6 and E7 proteins. J Cell Biochem 2008;105:81-8.
56. He X, Ota T, Liu P, Su C, Chien J, Shridhar V. Downregulation of HtrA1 promotes resistance to anoikis and peritoneal dissemination of ovarian cancer cells. Cancer Res 2010;70:3109-18.
57. Cai SL, Tee AR, Short JD, et al. Activity of TSC2 is inhibited by AKT-mediated phosphorylation and membrane partitioning. J Cell Biol 2006;173:279-89.